These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 32124136)
1. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG; Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Ito K; Blinder VS; Elkin EB J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313 [TBL] [Abstract][Full Text] [Related]
3. Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Tjan-Heijnen VCG; Int J Cancer; 2019 Sep; 145(5):1325-1333. PubMed ID: 30748011 [TBL] [Abstract][Full Text] [Related]
4. Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. Markopoulos C; Tzoracoleftherakis E; Koukouras D; Venizelos B; Zobolas V; Misitzis J; Xepapadakis G; Gogas H J Cancer Res Clin Oncol; 2012 Sep; 138(9):1569-77. PubMed ID: 22552718 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R; Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815 [TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334 [TBL] [Abstract][Full Text] [Related]
7. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE; J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719 [TBL] [Abstract][Full Text] [Related]
8. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007 [TBL] [Abstract][Full Text] [Related]
9. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Weycker D; Lamerato L; Schooley S; Macarios D; Siu Woodworth T; Yurgin N; Oster G Osteoporos Int; 2013 Apr; 24(4):1483-9. PubMed ID: 22903292 [TBL] [Abstract][Full Text] [Related]
10. Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer. Hirano A; Inoue H; Ogura K; Hattori A; Yukawa H; Sakaguchi S; Matsuoka A; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T Asia Pac J Clin Oncol; 2018 Oct; 14(5):e238-e242. PubMed ID: 29932305 [TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847 [TBL] [Abstract][Full Text] [Related]
12. Effects of bisphosphonates on long-term kidney transplantation outcomes. Song SH; Choi HY; Kim HY; Nam CM; Jeong HJ; Kim MS; Kim SII; Kim YS; Huh KH; Kim BS Nephrol Dial Transplant; 2021 Mar; 36(4):722-729. PubMed ID: 33367861 [TBL] [Abstract][Full Text] [Related]
13. Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Tang SC Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R; Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868 [TBL] [Abstract][Full Text] [Related]
15. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Safra T; Bernstein-Molho R; Greenberg J; Pelles-Avraham S; Stephansky I; Sarid D; Inbar MJ; Stemmer SM; Geffen DB Oncology; 2011; 81(5-6):298-305. PubMed ID: 22156381 [TBL] [Abstract][Full Text] [Related]
16. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer. Strobl S; Wimmer K; Exner R; Devyatko Y; Bolliger M; Fitzal F; Gnant M Curr Treat Options Oncol; 2018 Mar; 19(4):18. PubMed ID: 29527635 [TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R; J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H; Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292 [TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]